Indomethacin-Sopharma tab n / an kish.rastv. 25mg 30 pc

$1.40

Indomethacin-Sopharma tab n / an kish.rastv. 25mg 30 pc

5 in stock

Quantity:

SKU: 0375163864 Categories: , , Tags: ,

Description

Composition
Active substance:
1 tablet contains: indomethacin – 0.025 g
Product form:
Tablets 25 mg.
Contraindications
Hypersensitivity, “Aspirin” asthma, gastric ulcer and duodenal ulcer, ulcerative colitis, bleeding (intracranial, gastrointestinal), congenital heart defects (coarctation of the aorta, pulmonary atresia, tetralogy of Fallot), impaired color vision, liver cirrhosis with portal hypertension , optic nerve disease bronchial asthma, heart failure, hypertension, hemophilia, hypocoagulation, hepatic failure, chronic renal failure, hearing loss, Patolo tions of the vestibular apparatus, deficiency of glucose-6-phosphate dehydrogenase, blood diseases, rectal bleeding, proctitis, hemorrhoids.
Pregnancy, lactation, children under 14 years.
Carefully.
Hyperbilirubinemia, thrombocytopenia, epilepsy, Parkinson’s disease, depression, childhood and old age.
Dosage
25 mg
Indications
Inflammatory and degenerative diseases of the musculoskeletal rheumatoid arthritis, psoriatic, juvenile chronic arthritis, ankylosing spondylitis, rheumatic soft tissue, gouty arthritis.
As an adjuvant in combination therapy in infectious and inflammatory diseases of the upper respiratory tract, adnexitis, prostatitis, cystitis, neuritis, algodismenoree, headache and toothache.
Interaction with other drugs
Reduces the efficiency of uricosuric agents; antihypertensives and diuretics (saluretics) enhances the effect of anticoagulants, antiplatelet agents, fibrinolytics mineralokortikosteroidov side effects, estrogen al. NSAIDs, enhances hypoglycemic effect of sulfonylurea derivatives.
Sharing with paracetamol increases the risk of nephrotoxic effects. Ethanol, colchicine, corticosteroids – increase the risk of gastro-intestinal bleeding complications.
Antacids colestyramine and reduce absorption.
Increases concentration of lithium in blood preparations, methotrexate and digoxin. Cyclosporine, gold drugs increase the nephrotoxicity. Cefamandole, tsefaperazon, tsefotetan, valproic acid, plikamitsin – increase the risk of hypoprothrombinemia and the risk of bleeding. Potentiates the toxic effects of zidovudine. In infants increases the risk of toxic effects of aminoglycosides.
Overdose
Symptoms include nausea, vomiting, severe headache, dizziness, memory impairment, disorientation. In severe cases, paresthesia, numbness, convulsions.
Treatment: symptomatic therapy, hemodialysis ineffective.
pharmachologic effect
Pharmacological group:
Nonsteroidal anti-inflammatory drugs.
Pharmacodynamics:
Indomethacin has anti-inflammatory, analgesic, antipyretic and antiagregatsionnoe action. Suppresses pro-inflammatory factors, reduces platelet aggregation. Inhibiting cyclooxygenase 1 and 2, it gives the arachidonic acid metabolism, reduces the amount of prostaglandins (Pg) both in inflammation and in healthy tissue, inhibits the exudative and the proliferative phases of inflammation. Causes the attenuation or disappearance of pain syndrome, and rheumatoid rheumatic nature (including pain in the joints at rest and during motion, decrease of morning stiffness and joint swelling, increases range of motion; during inflammatory processes occurring after operations and traumas, facilitates fast as a spontaneous pain, and pain during movement reduces the inflammatory swelling at the wound site).
Pharmacokinetics:
Absorption – fast. Oral bioavailability – 98%. Maximum concentration upon ingestion (0.69 ug / ml) is achieved through – 2 h. The connection to plasma proteins – 90%. The half-life (T1 / 2) – 4 -. 9 h metabolized mainly – in the liver. Is output from the gastrointestinal tract – 30%. Not removed by dialysis. It passes into breast milk.
Conditions of supply of pharmacies
On prescription.
side effects
From the digestive system: NSAID gastropathy, abdominal pain, nausea, vomiting, heartburn, anorexia, diarrhea, abnormal liver function (increased bilirubin in the blood, “liver” of transaminases). With prolonged use of large doses -izyazvlenie mucosa of the gastrointestinal tract.
From the nervous system: headache, dizziness, insomnia, agitation, irritability, fatigue, drowsiness, depression, peripheral neuropathy.
From the senses: hearing loss, tinnitus, taste disturbance, diplopia, blurred vision, corneal opacity, conjunctivitis.
From the CCC: heart failure, tachyarrhythmia, increased blood pressure.
From the urinary system: renal dysfunction, Proteinuria, hematuria, interstitial nephritis, nephrotic syndrome, necrosis papillae.
On the part of the system of hemostasis: bleeding (gastrointestinal, gingival, uterine, hemorrhoids), thrombocytopenia.
Allergic reactions: skin rash, pruritus, urticaria, angioedema, bronchospasm, rarely -sindrom Lyell, erythema nodosum, anaphylactic shock.
Laboratory findings: agranulocytosis, leukopenia, hyperglycemia, glycosuria, hyperkalemia.
Other: aseptic meningitis (usually in patients with autoimmune diseases), aplastic anemia, autoimmune hemolytic anemia, edema syndrome, increased sweating.
Local reactions: burning, itching, heaviness in the anorectal area, worsening of hemorrhoids.
special instructions
During treatment requires monitoring picture peripheral blood and functional state of the liver and kidneys. If necessary, definition of 17-ketosteroids drug should be discontinued 48 hours before the study. It is necessary to monitor liver function, cellular composition of peripheral blood.
In the period of treatment should refrain from driving motor vehicles and activities potentially hazardous activities that require high concentration and psychomotor speed reactions.
To prevent and reduce dyspeptic symptoms should use antacids.
Storage conditions
In a dry place, protected from light.
Dosing and Administration
Inside, during or after a meal washed down with milk. Adults – at an initial dose of 25 mg of 2 – 3 times a day. With inadequate clinical response dose increased to 50 mg three times a day. The maximum daily dose – 200 mg.
Upon reaching the effect of treatment should be continued for 4 weeks in the same or a reduced dose. With prolonged use of the maximum daily dose – 75 mg.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

SOPHARMA

There are no reviews yet.

Add your review